Selenium (selenomethionine vs selenite) trials recruiting now
10 registrations that name selenium as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 10 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 10 registrations
RecruitingNCT07427017
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
Phase 2
Northwestern University
About 180 people
Started Apr 29, 2026
In plain words A Phase 2 study of selenium in people 18 to 85, run by Northwestern University. It plans to enroll about 180 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Ulcerative Colitis (UC).
Known or newly diagnosed moderate to severe UC (as defined by the modified Mayo score of 5-9; confirmed by clinical, endoscopic, and/or histopathological evidence prior to screening as per standard of care) who are either being started on…
The acceptable list of advanced therapies is (anti-TNF, anti-IL23, anti-integrin). For example, anti-tumor necrosis factor - infliximab, adalimumab, golimumab, certolizumab; anti-IL12/23 - ustekinumab, mirikizumab, risakizumab, guselkumab;…
Mayo endoscopic sub-score ≥2 (moderate to severe)
Mayo rectal bleeding sub-score ≥1 (moderate to severe)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Selenium supplementation; Placebo
Registered summary
Micronutrient deficiencies are common in ulcerative colitis (UC). Selenium deficiency is associated with worse disease outcomes including disease flares and need for surgery. Previous in vitro and in vivo studies demonstrated that selenium regulates colonic inflammation, and that selenium supplementation protects against DSS-induced colitis. In this proof-of-concept clinical trial, we aim to test the hypothesis that selenium supplementation in moderate to severely active UC patients will improve responsiveness to advanced therapy such as biologics and small molecules.
Where, as registered
1 US site in 1 state.
RecruitingNCT07543562
Selenium Intervention Registry Randomized Trial in Heart Failure
Phase 3
Skane University Hospital
About 4,326 people
Started Apr 1, 2026
In plain words A Phase 3 study of selenium in people 18 and older, run by Skane University Hospital. It plans to enroll about 4,326 people at 11 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure; Heart Failure and Reduced Ejection Fraction; Heart Failure and Mildly Reduced Ejection Fraction; Heart Failure and Preserved Ejection Fraction; Selenium Supplementation; Selenium; Cognitive Functioning.
18 years of age
primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry
be able to provide documented informed consent by signing and dating the designated consent form.
The exclusion criteria are on the listing.
What it tests, as registered
Selenium Supplement; Placebo
Registered summary
Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment. Selenium is an essential micronutrient that plays an important role in cellular energy production, antioxidant defense, and overall cardiovascular function. Low selenium levels are common among patients with heart failure in Northern Europe, and observational studies have shown that selenium deficiency is associated with an increased risk of hospitalization and death. The full summary is on the listing.
Where, as registered
No US site; Sweden (10), Norway (1).
RecruitingNCT06694727
A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure
Phase 3
Tor Biering-Sørensen
About 4,044 people
Started Sep 30, 2025
In plain words A Phase 3 study of selenium in people 18 and older, run by Tor Biering-Sørensen. It plans to enroll about 4,044 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure.
Individuals aged ≥ 18 years.
Registered with a heart failure diagnosis (ICD-10: I50) as a primary discharge diagnosis in The Danish National Patient Registry and at least one claimed prescription of a renin-angiotensin-system inhibitor and a β-blocker within 120 days…
Heart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk of complications associated with heart failure. The DANUTRIO-HF trial will investigate whether these supplements can make a difference for individuals with heart failure. The full summary is on the listing.
Where, as registered
No US site; Denmark (1).
RecruitingNCT07234422
The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
Phase 3
Netherlands Heart Institute
About 1,100 people
Started May 4, 2026
In plain words A Phase 3 study of selenium in people 18 and older, run by Netherlands Heart Institute. It plans to enroll about 1,100 people at 7 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Heart Failure.
Age >18 years
Outpatients with chronic HF, NYHA II - ambulatory IV
Serum NT-proBNP concentrations >600 pg/mL (71 pmol/L) if in sinus rhythm; >1000pg/mL (118 pmol/L) if in Atrial fibrillation*
The exclusion criteria are on the listing.
What it tests, as registered
Selenium/CoQ10; Matching Placebo (B)
Registered summary
The goal of this clinical trial is to learn whether taking selenium and coenzyme Q10 (CoQ10) can reduce HF related events and deaths related to cardiovascular disease. Researchers will compare selenium-CoQ10 supplements with a placebo to see if the supplements improve heart health and patient outcomes. Participants will: Receive either selenium-CoQ10 or placebo in addition to their usual heart failure treatment Attend standard clinical visits according to routine clinical care. The study will include 1,100 adults with chronic heart failure. The full summary is on the listing.
Where, as registered
No US site; Netherlands (7).
RecruitingNCT07203144
Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study
Phase 2
First Affiliated Hospital of Chongqing Medical University
About 172 people
Started Dec 31, 2025
In plain words A Phase 2 study of selenium in people 12 to 18, run by First Affiliated Hospital of Chongqing Medical University. It plans to enroll about 172 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 12 to 18. Conditions: Depression - Major Depressive Disorder.
Aged 12-18 years;
Diagnosed with major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), using the K-SADS-PL diagnostic tool;
A score of ≥40 on the Children's Depression Rating Scale-Revised (CDRS-R);
Adequate visual and auditory abilities to complete the study;
1 more inclusion criterion and the exclusion criteria are on the listing.
The purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.
Where, as registered
No US site; China (1).
RecruitingNCT04824053
Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development
No phase
Instituto de Investigación Sanitaria Aragón
About 34 people
Started Feb 28, 2022
In plain words A study of selenium in people 18 to 80, run by Instituto de Investigación Sanitaria Aragón. It plans to enroll about 34 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Colorectal Polyp.
Participants diagnosed with high-risk polyps in the colorectal cancer screening programme or in the relative's colon cancer prevention program or patients who are in follow-up due to prior detection of polyps with any of the following…
At least 10 adenomas
At least 5 proximal serrated polyps (PSP)
At least 2 serrated polyps with diameters ≥10 mm
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Milk from genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium; Conventional milk; Yogurt made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium; Conventional yogurt; Fresh cheese made from milk of genetically selected homozygous- β-casein-A2 cows fed with forages and a concentrate enriched on linseed and selenized yeast as sources of PUFAs and selenium; Conventional fresh cheese
Registered summary
Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy
Where, as registered
No US site; Spain (1).
RecruitingNCT06736015
Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)
No phase
Regina Elena Cancer Institute
About 30 people
Started Oct 23, 2024
In plain words A study of selenium in people 18 and older, run by Regina Elena Cancer Institute. It plans to enroll about 30 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Thyroid Nodule.
Adult (>18 years old),
both sexes,
patients presenting thyroid nodules classified as TIR 3A, based on cytological evaluation on sample from the first fine needle aspiration (FNA),
written Informed consent,
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Myo-Inositol 600 mg + Selenium 83 mcg
Registered summary
Thyroid nodules present a variable risk of malignancy depending on the cytological result obtained from the ultrasound-assisted thyroid fine needle aspiration biopsy. According to the Italian Cytology classification SIAPEC-IAP 2014, the TIR3A nodules are indeterminate nodules with a risk of malignancy lower than 10%. Clinical and instrumental follow-up is recommended in these cases, including repetition of the fine needle aspiration. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
Not yet recruitingNCT06264544
Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism
No phase
S.LAB (SOLOWAYS)
About 150 people
Starts Jul 30, 2025 (estimated)
In plain words A study of selenium in people 18 to 85, run by S.LAB (SOLOWAYS). It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Thyrotoxicosis.
Confirmed presence of one or more specified gene polymorphism r25191G/A SEPP1
TPOAb levels > 300 IU/mL
The exclusion criteria are on the listing.
What it tests, as registered
zinc, selenium, and L-tyrosine in SEPP1; Placebo
Registered summary
This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G/A SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant/breastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. The full summary is on the listing.
Where, as registered
No US site; Russia (1).
Not yet recruitingNCT07806474
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
No phase
Activ'inside
About 99 people
Starts Sep 30, 2026 (estimated)
In plain words A study of selenium in male participants 35 to 65, run by Activ'inside. It plans to enroll about 99 people at 6 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 35 to 65. Conditions: Androgenic Alopecia; Healthy Adult Male.
Healthy male subjects
Subjects of Caucasian ethnicity
Subjects aged between 35 and 65 years (extremes included)
Subjects with mild to moderate androgenetic alopecia, corresponding to the grade II to III vertex on Hamilton-Norwood scale
10 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast; formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast; Placebo (maltodextrin)
Registered summary
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic alopecia. The main questions it aims to answer are: * Whether the two formulations improve hair growth and reduce hair loss after 42 and 84 days, as assessed by phototricogram parameters. * Whether the two formulations improve hair brightness, and colour lightness after 42 and 84 days, as assessed by spectrophotometer/colorimeter. The full summary is on the listing.
Where, as registered
No US site; Italy (6).
Not yet recruitingNCT07334197
Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy
No phase
Tanta University
About 25 people
Starts Dec 20, 2026 (estimated)
In plain words A study of selenium in female participants 18 to 45, run by Tanta University. It plans to enroll about 25 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Ppm, Cardiomyopathy.
Women diagnosed with peripartum cardiomyopathy Age between 18-45 years. Left ventricular ejection fraction (LVEF) ≤ 45% at baseline. Able to provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Melatonin 10 MG; Selenium; Placebo
Registered summary
This randomized, controlled clinical trial investigates the potential cardioprotective effects of melatonin in women diagnosed with peripartum cardiomyopathy (PPCM). The study aims to determine whether melatonin supplementation improves left ventricular (LV) function, promotes reverse remodeling, and reduces systemic inflammation. The full summary is on the listing.